benefi t for bevacizumab. However, in colorectal cancer, a larger pooled analysis of VEGF-A concentrations showed a prognostic benefi t for this biomarker, but no predictive value for bevacizumab treatment. 16 A biomarker for anti-angiogenic treatment in patients with gastrointestinal cancers remains elusive.
Although ramucirumab might off er hope as a salvage treatment in patients with gastric cancer, is the modest benefi t reported in REGARD likely to be shown in all patients with treatment failure after fi rst-line therapy? Patients were selected on the basis of a fairly high per formance status and normal organ function. Gastric cancer is a highly aggressive disease with often rapid disease progression and clinical decline; therefore, the population in this study might not be indicative of all patients stopping initial therapy for metastatic disease. In view of the benefi t reported for patients with high functional status in this trial, the potential role of ramucirumab as a maintenance strategy might be a topic for future investigation. We now await with anticipation reporting of the ongoing trials of ramu cirumab combined with chemotherapy in early lines of therapy.
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Memorial Sloan-Kettering Cancer Center, New York, NY 10011, USA ilsond@mskcc.org I have been a consultant to Imclone Systems, Genentech, Amgen, and Clovis. 2 against disease caused by and carriage of sero group A meningococci in Chad. These fi ndings might fi nally usher in the beginning of elimination of sero group A meningococci in the meningitis belt, an endeavour that seems theoretically possible in view of the huge success of conjugate vaccines in abolishing disease caused by serogroup C meningococci in England and other countries. 3 Despite the availability and use of polysaccharide vaccines for the control of outbreaks since the 1970s, epidemics caused by serogroup A have continued to recur in the meningitis belt with incidence rates during outbreaks surpassing 300 cases per 100 000 population. 4 Daugla and coworkers 1 document the successful reduction of disease incidence by 94% after vaccination with PsA-TT, as compared with disease incidence in a region in which the vaccination campaign had not been carried out. Carriage prevalence of the epidemic strain was reduced by 98% after vaccination with PsA-TT. The vaccine's eff ect on carriage probably explains the absence of cases in residents too old (older than 30 years) or too young (younger than 1 year) to be immunised in vaccinated regions. The complete levelling of the expected rise in incidence in the fi rst quarter of 2012 impressively underscores the potential of PsA-TT for areas aff ected by serogroup A disease.
Results from studies in Burkina Faso, the fi rst country to start vaccination in December 2010, have already shown reduction of disease incidence, 5 elimination of carriage, 6 and a herd eff ect 5, 6 after vaccination with PsA-TT. However, by contrast with Chad, the campaign in Burkina Faso targeted the whole population aged 1-29 years, resulting in the vaccination of more than 11 million people within 10 days. 5 Nevertheless, as incidence rates were already falling sharply since 2007, 5 the reported vaccine eff ect might have been enhanced by natural waning of the disease. By contrast, the situation in Chad was diff erent; here, regions vaccinated in December, 2011 included only part of the population (roughly 1·8 million people), while extension of enhanced surveillance to a non-vaccinated district (Moissala) allowed concurrent comparison of incidence between vaccinated and unvaccinated areas. The investigators do not detail whether the populations in vaccinated and unvaccinated areas were indeed comparable; additionally, they state that selection of respective areas was not random. However, because disease progression had been consistent in both areas before vaccination, the assumption that the populations were indeed similar is plausible. The presented study design 1 allows a more accurate assessment of vaccine eff ect than do designs with purely temporal controls. 6, 7 Daugla and colleagues' study would not have been possible without the MVP, which exemplifi es how an infectious disease can be tackled without the help of multinational companies with little interest in entering markets off ering low profi t margins. Although the MVP represents an innovative development programme between high-income and low-income countries, it also encourages collaboration between low-income countries-eg, between India as a producer and African countries as consumers of a biotechnology product. This new approach, worthy of replication and extension, was also honoured in the Brazil-Cuba meningitis project. 8 The report further highlights the urgent need for high quality surveillance systems for the assessment of vaccine eff ectiveness. However, establishment of high quality surveillance is very challenging, as shown by the inability of researchers, who report implementation of enhanced surveillance in the vaccinated and unvaccinated areas for the duration of the dry season, to estimate one of their system's most basic properties: completeness of case ascertainment. 1 Apart from measurement of vaccine eff ect, surveillance systems should be able to warn about possible serogroup replacement. 9 Although episodes of capsule switching have been reported in countries using vaccines against serogroup C, 10,11 these episodes were generally not widespread or lasting. Nevertheless, because experience of elimination of serogroup A by glycoconjugate vaccines is limited, and capsule replacement was also shown for other bacteria including pneumococci, 12 the establishment of surveillance systems needs to be prioritised. Further research should focus on the development and validation of serological correlates of protection and on the establishment of improved methods for detection of carriage, 9 because exact duration of protection and Understanding of adhesion formation after abdominal surgery and its unwanted eff ects can be traced back to the advent of intra-abdominal surgery. Weibel and Majno 1 described the eff ect of abdominal surgical interventions in post-mortem studies, noting abdominal adhesions in 67% of patients who had previous abdominal surgery. Many subsequent studies have supported this fi nding and indicated even higher rates of adhesion formation after abdominal surgery.
In an attempt to explain the pathogenesis of peritoneal adhesions, Schade and Williamson 2 undertook ultra structural analysis of adhesions in rodents and con cluded that desquamation of mesothelial cells, leaving a denuded surface, seemed to be the critical event in adhesion formation. Subsequently, Buckman and col leagues 3 thought that fi brin was deposited on an exposed basement membrane, and failure to clear this deposited fi brin due to local depression of plasminogen activator activity was the unifying mechanism of ab dominal ad hesion formation.
Present understanding is that adhesion formation is a normal part of wound healing, with various factors determining either resolution or pathological adhesion formation. 4 Schade and Williamson's work 2 formed the scientifi c basis for changes in surgical techniques, which aim to reduce tissue handling and limit tissue damage and adhesion formation. To prevent intraperitoneal adhe sions after repeat laparotomies, intraperitoneal application of paraffi n, camphor, air insuffl ation, and amnion was recom mended by Kubanyl, 5 who also pointed out that no reliable method to prevent abdominal adhesions existed. This pessimistic view resonates to the present day, and often leads to fatalistic acceptance of postoperative abdominal adhesion for mation rather than use of an active approach to reduce or prevent adhesions in routine surgical practice. 6 Many drugs have been administered both topically and systemically in an attempt to reduce adhesion formation, Adhesion barriers for abdominal surgery: a sticky problem age-stratifi ed carriage prevalences are needed for the identifi cation of optimum vaccination strategies. 13 Although the paper by Daugla and colleagues 1 represents an important milestone in the battle against meningococcal disease, many more mysteries regarding meningococci await clarifi cation; thus, the jury remains out as to why serogroup A, prevalent in the northern hemisphere until the 1980s, has mostly disappeared from Europe, 14 and why, with a few ephemeral exceptions, 15 it has not been successfully reintroduced into industrialised countries despite frequent travel.
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